RAPT Research and Charts

RAPT - RAPT Therapeutics Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-01-06)

Last 1.72	Change ⇑ +0.05 (+2.99%)	Volume 1,180,019
	Open 1.67	High 1.73	Low 1.60

8EMA (Daily) 1.59	40EMA (Daily) 1.45	50EMA (Daily) 1.50	STO (Daily) 55.817	MACD Hist (Daily) 0.137
8EMA (Weekly) 1.494	40EMA (Weekly) 4.21	50EMA (Weekly) 5.42	STO (Weekly) 21.739	MACD Hist (Weekly) 0.614


Company Profile
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.